Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy

Roberto Ronca; Arianna Giacomini; Emanuela Di Salle; Daniela Coltrini; Katiuscia Pagano; Laura Ragona; Sara Matarazzo; Sara Rezzola; Daniele Maiolo; Rubben Torrella; Elisabetta Moroni; Roberta Mazzieri; Giulia Escobar; Marco Mor; Giorgio Colombo; Marco Presta

doi:10.1016/j.ccell.2015.07.002

Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy

Roberto Ronca, Arianna Giacomini, Emanuela Di Salle, Daniela Coltrini, Katiuscia Pagano, Laura Ragona, Sara Matarazzo, Sara Rezzola, Daniele Maiolo, Rubben Torrella, Elisabetta Moroni, Roberta Mazzieri, Giulia Escobar, Marco Mor, Giorgio Colombo, Marco Presta

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

The fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a crucial role in cancer by affecting tumor growth, angiogenesis, drug resistance, and escape from anti-angiogenic anti-vascular endothelial growth factor therapy. The soluble pattern recognition receptor long-pentraxin 3 (PTX3) acts as a multi-FGF antagonist. Here we demonstrate that human PTX3 overexpression in transgenic mice driven by the Tie2 promoter inhibits tumor growth, angiogenesis, and metastasis in heterotopic, orthotopic, and autochthonous FGF-dependent tumor models. Using pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding pentapeptide with FGF2, we identified a small-molecule chemical (NSC12) that acts as an extracellular FGF trap with significant implications in cancer therapy. Ronca et al. show that overexpression of long-pentraxin 3 (PTX3) in mice inhibits the growth of FGF-dependent tumor models. On the basis of pharmacophore modeling of PTX3-FGF2 interaction, they identify a small molecule that acts as an extracellular FGF trap and inhibits FGF-dependent tumor growth in mice.

Original language	English
Pages (from-to)	225-239
Number of pages	15
Journal	Cancer Cell
Volume	28
Issue number	2
DOIs	https://doi.org/10.1016/j.ccell.2015.07.002
Publication status	Published - Aug 10 2015

Fingerprint

ASJC Scopus subject areas

Cancer Research
Cell Biology
Oncology
Medicine(all)

Cite this

Ronca, R., Giacomini, A., Di Salle, E., Coltrini, D., Pagano, K., Ragona, L., Matarazzo, S., Rezzola, S., Maiolo, D., Torrella, R., Moroni, E., Mazzieri, R., Escobar, G., Mor, M., Colombo, G., & Presta, M. (2015). Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. Cancer Cell, 28(2), 225-239. https://doi.org/10.1016/j.ccell.2015.07.002

Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. / Ronca, Roberto; Giacomini, Arianna; Di Salle, Emanuela; Coltrini, Daniela; Pagano, Katiuscia; Ragona, Laura; Matarazzo, Sara; Rezzola, Sara; Maiolo, Daniele; Torrella, Rubben; Moroni, Elisabetta; Mazzieri, Roberta; Escobar, Giulia; Mor, Marco; Colombo, Giorgio; Presta, Marco.

In: Cancer Cell, Vol. 28, No. 2, 10.08.2015, p. 225-239.

Research output: Contribution to journal › Article

Ronca, Roberto ; Giacomini, Arianna ; Di Salle, Emanuela ; Coltrini, Daniela ; Pagano, Katiuscia ; Ragona, Laura ; Matarazzo, Sara ; Rezzola, Sara ; Maiolo, Daniele ; Torrella, Rubben ; Moroni, Elisabetta ; Mazzieri, Roberta ; Escobar, Giulia ; Mor, Marco ; Colombo, Giorgio ; Presta, Marco. / Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. In: Cancer Cell. 2015 ; Vol. 28, No. 2. pp. 225-239.

@article{fc5f08d2afae4df9a1d55f347521fa35,

title = "Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy",

abstract = "The fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a crucial role in cancer by affecting tumor growth, angiogenesis, drug resistance, and escape from anti-angiogenic anti-vascular endothelial growth factor therapy. The soluble pattern recognition receptor long-pentraxin 3 (PTX3) acts as a multi-FGF antagonist. Here we demonstrate that human PTX3 overexpression in transgenic mice driven by the Tie2 promoter inhibits tumor growth, angiogenesis, and metastasis in heterotopic, orthotopic, and autochthonous FGF-dependent tumor models. Using pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding pentapeptide with FGF2, we identified a small-molecule chemical (NSC12) that acts as an extracellular FGF trap with significant implications in cancer therapy. Ronca et al. show that overexpression of long-pentraxin 3 (PTX3) in mice inhibits the growth of FGF-dependent tumor models. On the basis of pharmacophore modeling of PTX3-FGF2 interaction, they identify a small molecule that acts as an extracellular FGF trap and inhibits FGF-dependent tumor growth in mice.",

author = "Roberto Ronca and Arianna Giacomini and {Di Salle}, Emanuela and Daniela Coltrini and Katiuscia Pagano and Laura Ragona and Sara Matarazzo and Sara Rezzola and Daniele Maiolo and Rubben Torrella and Elisabetta Moroni and Roberta Mazzieri and Giulia Escobar and Marco Mor and Giorgio Colombo and Marco Presta",

year = "2015",

month = aug

day = "10",

doi = "10.1016/j.ccell.2015.07.002",

language = "English",

volume = "28",

pages = "225--239",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy

AU - Ronca, Roberto

AU - Giacomini, Arianna

AU - Di Salle, Emanuela

AU - Coltrini, Daniela

AU - Pagano, Katiuscia

AU - Ragona, Laura

AU - Matarazzo, Sara

AU - Rezzola, Sara

AU - Maiolo, Daniele

AU - Torrella, Rubben

AU - Moroni, Elisabetta

AU - Mazzieri, Roberta

AU - Escobar, Giulia

AU - Mor, Marco

AU - Colombo, Giorgio

AU - Presta, Marco

PY - 2015/8/10

Y1 - 2015/8/10

N2 - The fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a crucial role in cancer by affecting tumor growth, angiogenesis, drug resistance, and escape from anti-angiogenic anti-vascular endothelial growth factor therapy. The soluble pattern recognition receptor long-pentraxin 3 (PTX3) acts as a multi-FGF antagonist. Here we demonstrate that human PTX3 overexpression in transgenic mice driven by the Tie2 promoter inhibits tumor growth, angiogenesis, and metastasis in heterotopic, orthotopic, and autochthonous FGF-dependent tumor models. Using pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding pentapeptide with FGF2, we identified a small-molecule chemical (NSC12) that acts as an extracellular FGF trap with significant implications in cancer therapy. Ronca et al. show that overexpression of long-pentraxin 3 (PTX3) in mice inhibits the growth of FGF-dependent tumor models. On the basis of pharmacophore modeling of PTX3-FGF2 interaction, they identify a small molecule that acts as an extracellular FGF trap and inhibits FGF-dependent tumor growth in mice.

AB - The fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a crucial role in cancer by affecting tumor growth, angiogenesis, drug resistance, and escape from anti-angiogenic anti-vascular endothelial growth factor therapy. The soluble pattern recognition receptor long-pentraxin 3 (PTX3) acts as a multi-FGF antagonist. Here we demonstrate that human PTX3 overexpression in transgenic mice driven by the Tie2 promoter inhibits tumor growth, angiogenesis, and metastasis in heterotopic, orthotopic, and autochthonous FGF-dependent tumor models. Using pharmacophore modeling of the interaction of a minimal PTX3-derived FGF-binding pentapeptide with FGF2, we identified a small-molecule chemical (NSC12) that acts as an extracellular FGF trap with significant implications in cancer therapy. Ronca et al. show that overexpression of long-pentraxin 3 (PTX3) in mice inhibits the growth of FGF-dependent tumor models. On the basis of pharmacophore modeling of PTX3-FGF2 interaction, they identify a small molecule that acts as an extracellular FGF trap and inhibits FGF-dependent tumor growth in mice.

UR - http://www.scopus.com/inward/record.url?scp=84939444543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939444543&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2015.07.002

DO - 10.1016/j.ccell.2015.07.002

M3 - Article

C2 - 26267536

AN - SCOPUS:84939444543

VL - 28

SP - 225

EP - 239

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 2

ER -

Access to Document

10.1016/j.ccell.2015.07.002